期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 19, 期 9, 页码 -出版社
MDPI
DOI: 10.3390/ijms19092571
关键词
fibroblast-to-myofibroblast transition; TGF-beta/Smad signaling; fenofibrate; bronchial asthma; actin cytoskeleton architecture; connexin 43
资金
- Polish National Science Centre [2015/17/B/NZ3/02248]
- Ministry of Science and Higher Education
The activation of human bronchial fibroblasts by transforming growth factor-beta(1) (TGF-beta(1)) leads to the formation of highly contractile myofibroblasts in the process of the fibroblast-myofibroblast transition (FMT). This process is crucial for subepithelial fibrosis and bronchial wall remodeling in asthma. However, this process evades current therapeutic asthma treatment strategies. Since our previous studies showed the attenuation of the TGF-beta(1)-induced FMT in response to lipid-lowering agents (e.g., statins), we were interested to see whether a corresponding effect could be obtained upon administration of hypolipidemic agents. In this study, we investigated the effect of fenofibrate on FMT efficiency in populations of bronchial fibroblasts derived from asthmatic patients. Fenofibrate exerted a dose-dependent inhibitory effect on the FMT, even though it did not efficiently affect the expression of alpha-smooth muscle actin (alpha-SMA; marker of myofibroblasts); however, it considerably reduced its incorporation into stress fibers through connexin 43 regulation. This effect was accompanied by disturbances in the actin cytoskeleton architecture, impairments in the maturation of focal adhesions, and the fenofibrate-induced deactivation of TGF-beta(1)/Smad2/3 signaling. These data suggest that fenofibrate interferes with myofibroblastic differentiation during asthma-related subepithelial fibrosis. The data indicate the potential application of fenofibrate in the therapy and prevention of bronchial remodeling during the asthmatic process.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据